Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$59.78

-0.7252 (-1.20%)

, AZN

AstraZeneca

$26.70

-0.4 (-1.48%)

10:01
11/28/16
11/28
10:01
11/28/16
10:01

Citi analyst 'perturbed,' downgrades AbbVie to Neutral

Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.

ABBV

AbbVie

$59.78

-0.7252 (-1.20%)

AZN

AstraZeneca

$26.70

-0.4 (-1.48%)

LLY

Eli Lilly

$67.85

-1.2686 (-1.84%)

BMY

Bristol-Myers

$56.76

-0.22 (-0.39%)

  • 29

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 16

    Feb

ABBV AbbVie
$59.78

-0.7252 (-1.20%)

11/08/16
BARD
11/08/16
NO CHANGE
Target $40
BARD
Outperform
Coherus Biosciences weakness a buying opportunity, says Baird
Baird analyst Michael Ulz noted Coherus (CHRS) received a decision denying the institution of the '166 IPR related to Abbie's (ABBV) Humira. Though the decision was disappointing, the analyst sees multiple opportunities remaining to circumvent the patent. Ulz said he would be a buyer on the weakness in Coherus and reiterated his Outperform rating and $40 price target on the shares.
11/07/16
COWN
11/07/16
NO CHANGE
Target $45
COWN
Outperform
Coherus has other paths to pursue in AbbVie patent fight, says Cowen
Cowen analyst Ken Cacciatore noted the U.S. Patent Trial and Appeals Board decided to deny institution of Coherus Biosciences' (CHRS) Inter Partes Review against AbbVie's (ABBV) '166 patent related to Humira, though he believes that Coherus still has other remaining pathways in its patent fight over the drug. "Today's news, although a setback, should be treated as a relatively minor" one, he tells investors. Cacciatore has an Outperform rating and $45 price target on Coherus shares.
11/07/16
SBSH
11/07/16
NO CHANGE
Target $36
SBSH
Buy
Citi says buy Coherus Biosciences on today's selloff
Citi analyst Mohit Bansal recommends using today's selloff in shares of Coherus Biosciences (CHRS) as a buying opportunity. Checks with patent experts indicate that the patent in today's case is not a key obstacle against a biosimilar of AbbVie's Humira, Bansal tells investors in a research note. Further, the analyst estimates fair value of Coherus shares at $24 if the Humira biosimilar is removed completely. The stock is currently down 16%, or $4.60, to $23.55. Basel does not expect a biosimilar launch until 2020. He adds that every one year launch delay post 2020 would impact his fair value for shares by only $1. The analyst keeps a Buy rating on Coherus with a $36 price target.
11/28/16
SBSH
11/28/16
DOWNGRADE
SBSH
Neutral
AbbVie downgraded to Neutral from Buy at Citi
AZN AstraZeneca
$26.70

-0.4 (-1.48%)

10/26/16
PIPR
10/26/16
NO CHANGE
PIPR
Neutral
Piper still uncertain on Clovis position after AstraZeneca data
AstraZeneca's (AZN) Phase III study of Lynparza in ovarian cancer "substantially improved" progression-free survival over what was seen in study 19, suggesting a profile at least similar to TESARO's (TSRO) niraparib, Piper Jaffray analyst Steven Breazzano tells investors in a research note. The new data confirm that the various PARP inhibitors are more similar than different, which bodes well for Clovis Oncology's (CLVS) own maintenance study, the analyst contends. Breazzano, however, remains the sidelines with respect to Clovis shares given the "increasingly competitive dynamic" in ovarian cancer and uncertainty in the company's position in the important maintenance setting. The analyst keeps a Neutral rating on Clovis.
10/20/16
JANY
10/20/16
NO CHANGE
Target $1.5
JANY
Neutral
Cerulean cash infusion gives chance to execute on programs, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Cerulean's (CERU) collaboration with Novartis (NVS), which comes with a "modest" $5M upfront payment, and its $20M ATM facility with Aspire Capital, while "not ideal," gives management a chance to execute on three of its ongoing programs, the most important of which is the dose escalation study with Olaparib with partner AstraZeneca (AZN) that should have preliminary data in 2Q17. The analyst raised his fair value estimate on Cerulean to $1.50 from $1.00 and keeps a Neutral rating on the stock.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
LLY Eli Lilly
$67.85

-1.2686 (-1.84%)

11/25/16
BARD
11/25/16
NO CHANGE
Target $29
BARD
Outperform
Lilly trial failure has little to do with Axovant Sciences, says Baird
Baird analyst Brian Skorney said Eli Lilly's (LLY) solanezumab drug trial failure has little to do with Axovant Sciences (AXON) drug trial for Alzheimer's. The analyst said Lilly's failure is a reminder of the difficulty of the disease, but the two company's drugs are very different and meant to have very different effects. Skorney reiterated his Outperform rating and $29 price target on Axovant shares.
11/25/16
ATLE
11/25/16
DOWNGRADE
ATLE
Neutral
Eli Lilly downgraded to Neutral from Overweight at Atlantic Equities
11/28/16
BOFA
11/28/16
NO CHANGE
BOFA
Buy
Eli Lilly removed from US 1 List at BofA/Merrill
11/28/16
MAXM
11/28/16
NO CHANGE
Target $15
MAXM
Buy
Anavex may be targeting 'ideal approach' to Alzheimer's disease, says Maxim
After Eli Lilly's (LLY) solanezumab failed its third Phase 3 study in early-stage Alzheimer's disease, Maxim analyst Jason McCarthy noted that Anavex's (AVXL) 2-73 targets the disease "more broadly upstream" to restore proper CNS cell function and has shown "promising early data." While too soon to draw any firm conclusions, given the lessons learned from failures in pursuit of other avenues, Anavex "may be on the right track" by looking upstream, said McCarthy, who keeps a Buy rating and $15 price target on the stock.
BMY Bristol-Myers
$56.76

-0.22 (-0.39%)

11/03/16
JPMS
11/03/16
NO CHANGE
JPMS
JPMorgan calls Lilly, Bristol-Myers, Allergan favorite pharma majors
Following a "challenging" Q3 earnings season for the major pharmaceuticals companies, JPMorgan analyst Chris Schott said pricing continues to be a major overhang on the space. However, he believes these and other challenges are "increasingly well reflected" in both earnings and sector multiples and recommends companies early in new product launch cycles. Coming out of the earnings season, Schott named Eli Lilly (LLY), Bristol-Myers (BMY) and Allergan (AGN) as his favorite names in the large-cap pharma space.
10/28/16
10/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein saying the stock's valuation now "properly" reflects the challenging fundamental outlook. 2. Bristol-Myers (BMY) upgraded to Long-Term Buy from Neutral at Hilliard Lyons. 3. Qualcomm (QCOM) upgraded on valuation at BMO Capital with analyst Tim Long saying he is neutral on Qualcomm's acquisition of NXP (NXPI), but he expects Qualcomm's stock to stay in a trading range in the wake of the deal. 4. Level 3 (LVTL) upgraded to Outperform from Perform at Oppenheimer with analyst Timothy Horan saying the company has restructured itself in the last few years and now has operational/financial flexibility on free cash flow, with the analyst seeing accelerating growth in 2017. 5. ConocoPhillips (COP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company reported "another solid quarter." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/28/16
HDLY
10/28/16
UPGRADE
HDLY
Long-Term Buy
Bristol-Myers upgraded to Long-Term Buy from Neutral at Hilliard Lyons

TODAY'S FREE FLY STORIES

SO

Southern Company

$50.50

0.83 (1.67%)

15:07
02/25/17
02/25
15:07
02/25/17
15:07
Conference/Events
Southern Company participates in a conference call with Wolfe Research »

Wolfe Utilties Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 03

    Mar

DK

Delek US

$23.19

-0.21 (-0.90%)

15:04
02/25/17
02/25
15:04
02/25/17
15:04
Conference/Events
Delek US management participates in a dinner meeting with Wolfe Research »

Wolfe Gas & Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ANTM

Anthem

$163.83

-0.09 (-0.05%)

15:00
02/25/17
02/25
15:00
02/25/17
15:00
Conference/Events
Anthem management to meet with Wolfe Research »

Wolfe Healthcare Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MCO

Moody's

$113.29

0.06 (0.05%)

14:56
02/25/17
02/25
14:56
02/25/17
14:56
Conference/Events
Moody's analysts participate in a meeting with Wolfe Research »

Wolfe Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 05

    Mar

ONCS

OncoSec

$1.39

-0.03 (-2.11%)

, NKTR

Nektar

$13.45

0.25 (1.89%)

04:55
02/25/17
02/25
04:55
02/25/17
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2017 ASCO-SITC Clinical…

ONCS

OncoSec

$1.39

-0.03 (-2.11%)

NKTR

Nektar

$13.45

0.25 (1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MMM

3M

$187.41

0.22 (0.12%)

, BIOL

BIOLASE

$1.49

-0.01 (-0.67%)

04:55
02/25/17
02/25
04:55
02/25/17
04:55
Conference/Events
Chicago Dental Society to hold a meeting »

Chicago Dental Midwinter…

MMM

3M

$187.41

0.22 (0.12%)

BIOL

BIOLASE

$1.49

-0.01 (-0.67%)

COF

Capital One

$92.61

-0.8 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNECY

Renesas

$4.14

-0.17 (-3.94%)

, ISIL

Intersil

19:04
02/24/17
02/24
19:04
02/24/17
19:04
Hot Stocks
Renesas sees Intersil acquisition accretive to non-GAAP EPS, free cash flows »

Renesas Electronics…

RNECY

Renesas

$4.14

-0.17 (-3.94%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSIC

Henry Schein

$173.53

1.61 (0.94%)

18:45
02/24/17
02/24
18:45
02/24/17
18:45
Conference/Events
Henry Schein management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

TWX

Time Warner

$97.28

0.6225 (0.64%)

18:38
02/24/17
02/24
18:38
02/24/17
18:38
Periodicals
Turner, Univision to win U.S. Champions League rights, Bloomberg reports »

Turner, a subsidiary of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRUE

TrueCar

$14.28

0.18 (1.28%)

18:33
02/24/17
02/24
18:33
02/24/17
18:33
Hot Stocks
TrueCar's ALG sees February total new vehicle sales 1.325M units, down 1.4% »

ALG projects total new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

GE

General Electric

$30.19

0.17 (0.57%)

18:24
02/24/17
02/24
18:24
02/24/17
18:24
Hot Stocks
GE does not see after-tax charges from GE Capital exit plan to exceed $23B »

GE said in a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CE

Celanese

$88.79

-0.88 (-0.98%)

18:02
02/24/17
02/24
18:02
02/24/17
18:02
Hot Stocks
Celanese announces vinyl acetate-based emulsions price increases in Asia »

Celanese announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ELNK

EarthLink

$5.63

-0.22 (-3.76%)

, WIN

Windstream

$7.27

-0.02 (-0.27%)

17:56
02/24/17
02/24
17:56
02/24/17
17:56
Hot Stocks
EarthLink, Windstream holders approve merger »

EarthLink (ELNK)…

ELNK

EarthLink

$5.63

-0.22 (-3.76%)

WIN

Windstream

$7.27

-0.02 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

PFE

Pfizer

$34.26

0.2 (0.59%)

17:43
02/24/17
02/24
17:43
02/24/17
17:43
Periodicals
Pfizer subpoenaed in investigation of charity connections, Bloomberg says »

Pfizer has received two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 09

    Mar

  • 17

    Mar

  • 23

    Mar

  • 01

    Apr

C

Citi

$59.56

-1.06 (-1.75%)

17:32
02/24/17
02/24
17:32
02/24/17
17:32
Hot Stocks
U.S. regulators investigating Citi over foreign hiring practices »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

FDX

FedEx

$193.11

1.93 (1.01%)

17:25
02/24/17
02/24
17:25
02/24/17
17:25
Hot Stocks
FedEx, USPS amend transportation agreement »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

URRE

Uranium Resources

$1.94

-0.09 (-4.43%)

17:21
02/24/17
02/24
17:21
02/24/17
17:21
Syndicate
Breaking Syndicate news story on Uranium Resources »

Uranium Resources files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$153.48

0.19 (0.12%)

17:13
02/24/17
02/24
17:13
02/24/17
17:13
Hot Stocks
Raytheon awarded $1B government contract »

Raytheon Co., Woburn,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COTV

Cotiviti Holdings

$38.74

-0.06 (-0.15%)

17:06
02/24/17
02/24
17:06
02/24/17
17:06
Syndicate
Breaking Syndicate news story on Cotiviti Holdings »

Cotiviti Holdings files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

ENH

Endurance Specialty

$92.90

0.02 (0.02%)

17:05
02/24/17
02/24
17:05
02/24/17
17:05
Earnings
Endurance reports Q4 EPS 30c, may not compare to consensus $1.26 »

Reports Q4 gross premiums…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORPN

Bio Blast Pharma

$1.13

-0.0098 (-0.86%)

17:04
02/24/17
02/24
17:04
02/24/17
17:04
Syndicate
Breaking Syndicate news story on Bio Blast Pharma »

Bio Blast Pharma files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.40

0.3 (1.99%)

, PFE

Pfizer

$34.26

0.2 (0.59%)

16:44
02/24/17
02/24
16:44
02/24/17
16:44
General news
On The Fly: Stocks end week higher as rally continues »

Stocks ended the week…

MNTA

Momenta

$15.40

0.3 (1.99%)

PFE

Pfizer

$34.26

0.2 (0.59%)

STLD

Steel Dynamics

$35.59

0.07 (0.20%)

AKS

AK Steel

$8.02

-0.1 (-1.23%)

X

U.S. Steel

$37.01

-0.3 (-0.80%)

FLR

Fluor

$55.09

-0.26 (-0.47%)

GVA

Granite Construction

$53.91

0.78 (1.47%)

VMC

Vulcan Materials

$117.82

1.47 (1.26%)

PWR

Quanta Services

$37.76

0.62 (1.67%)

ACM

AECOM

$35.77

-0.58 (-1.60%)

JEC

Jacobs Engineering

$56.03

-0.07 (-0.12%)

KBR

KBR

$15.60

-0.55 (-3.41%)

CBI

CB&I

$33.87

-0.02 (-0.06%)

MTZ

MasTec

$40.10

3.05 (8.23%)

KHC

Kraft Heinz

$93.08

0.14 (0.15%)

UN

Unilever; also tag UL

$46.91

0.33 (0.71%)

UL

Unilever; also tag UN

$47.12

0.22 (0.47%)

QSR

Restaurant Brands

$55.47

-0.08 (-0.14%)

PLKI

Popeyes

TROX

Tronox

$17.40

-0.67 (-3.71%)

WMT

Wal-Mart

$72.39

1.08 (1.51%)

HD

Home Depot

$145.95

1.24 (0.86%)

CYH

Community Health

$9.22

0.32 (3.60%)

TOL

Toll Brothers

$33.74

-0.22 (-0.65%)

GRMN

Garmin

$53.03

0.72 (1.38%)

CHS

Chico's

$14.75

0.3 (2.08%)

HPQ

HP Inc.

$17.65

0.05 (0.28%)

CRI

Carter's

$90.04

2.98 (3.42%)

SQ

Square

$17.43

0.28 (1.63%)

JWN

Nordstrom

$46.46

2.52 (5.74%)

FL

Foot Locker

$75.01

6.43 (9.38%)

AAOI

Applied Optoelectronics

$45.98

8.51 (22.71%)

RH

Restoration Hardware

$31.34

6.15 (24.41%)

M

Macy's

$33.17

0.73 (2.25%)

PZZA

Papa John's

$78.70

-0.07 (-0.09%)

FSLR

First Solar

$37.90

0.71 (1.91%)

TXRH

Texas Roadhouse

$42.22

0.13 (0.31%)

TSLA

Tesla

$257.00

1.01 (0.39%)

LB

Labarge

$50.99

2.05 (4.19%)

W

Wayfair

$39.30

0.72 (1.87%)

HPE

HP Enterprise

$22.96

-1.7 (-6.89%)

JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

ACIA

Acacia Communications

$54.04

-9.39 (-14.80%)

BGS

B&G Foods

$43.65

-3.25 (-6.93%)

SPLK

Splunk

$62.80

-2.1 (-3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 03

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 07

    Mar

  • 09

    Mar

  • 09

    Mar

  • 14

    Mar

  • 15

    Mar

  • 17

    Mar

  • 19

    Mar

  • 21

    Mar

  • 23

    Mar

  • 23

    Mar

  • 28

    Mar

  • 01

    Apr

  • 04

    Apr

  • 05

    Apr

  • 17

    Apr

NBEV

New Age Beverages

$3.90

-0.04 (-1.02%)

16:41
02/24/17
02/24
16:41
02/24/17
16:41
Hot Stocks
Breaking Hot Stocks news story on New Age Beverages »

Park West AM reports 6.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$1.71

-0.07 (-3.93%)

16:40
02/24/17
02/24
16:40
02/24/17
16:40
Hot Stocks
Breaking Hot Stocks news story on Cytori Therapeutics »

Azaya Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMA

ADMA Biologics

$4.75

-0.03 (-0.63%)

16:40
02/24/17
02/24
16:40
02/24/17
16:40
Earnings
ADMA Biologics reports FY16 EPS ($1.61), consensus ($1.57) »

Reports FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.